Immuneering Q3 2026 net loss $24.2M; MAPKeeper 301 enrollment ahead of schedule, runway to 4Q 2028

Immuneering Corp

Net loss attributable to common stockholders $24.2M, or $0.37/share, vs $15.0M ($0.38/share) in Q3 2025; R&D $20.7M vs $10.9M on higher clinical and personnel costs.
Cash, cash equivalents and marketable securities $166.1M at Sept 30, 2026, down from $217.0M at Dec 31, 2025; runway now funded into 4Q 2028.
Phase 2 1L pancreatic cancer atebimetinib + mGnP arm (N=55) follow-up extended because patients are living longer than projected; topline update now 1H 2027.
Phase 3 MAPKeeper 301 enrollment ahead of schedule; target expanded from 510 to ~570 patients, with potential to accelerate current mid-2028 topline guidance.
CEO Zeskind cited 17.3 months median overall survival reported at ASCO; first lung cancer patient in atebimetinib + cemiplimab Phase 2 dosed in 4Q 2026.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.